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Background: Invasive micropapillary carcinoma (IMPC) of the breast is a rare and aggressive
variant of invasive ductal carcinoma. IMPC has been reported to account for 3–6% of all breast
cancers, and these tumors have been associated with a strong tendency to invade lymphatics
with early spread to regional lymph nodes.
Patients and methods: We present a case of this rare type of breast cancer diagnosed in a
male patient and summarize the current literature to date.
Results: Review of the literature on invasive micropapillary breast carcinoma revealed 27
retrospective cohort studies and case series. Signiﬁcant heterogeneity of inclusion criteria and
follow up data prevented meta-analysis. Tumors with an IMPC component demonstrated an
early and high rate of lymphatic metastasis compared to invasive ductal carcinoma, however,
no signiﬁcant association was found between IMPC and decreased overall survival.
Conclusions: The IMPC data currently available indicates a strong trend towards a higher
initial stage at diagnosis and possibly an increased risk of loco-regional recurrence, but remains
underpowered to elucidate the prognostic effect of IMPC phenotype on survival. Further studies
are warranted to establish the potential of this unique histologic phenotype to serve as a
prognostic indicator and guide tumor-speciﬁc oncologic therapy.
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c.org (J.T. Stranix).1. Introduction
Invasive micropapillary carcinoma (IMPC) is a rare variant of
invasive ductal carcinoma of the breast ﬁrst described as aen access article under the CC BY-NC-ND license
Figure 1 High power view of breast tissue from our patient
demonstrating invasive ductal carcinoma with micropapillary
differentiation showing neoplastic cells surrounded by loose
ﬁbrocollagenous stroma.
Figure 2 Low power view of breast tissue from our patient
demonstrating invasive ductal carcinoma with micropapillary
differentiation and lymphovascular invasion.
45Invasive micropapillary carcinomadistinct histologic subtype by both Petersen [1] and Siriaunk-
gul [2] in 1993. Further evidence suggests it may constitute a
distinct entity from invasive ductal carcinoma at the mole-
cular genetic level as well [3]. Histopathologically, IMPC is
characterized by neoplastic cells in a nested papillary
pattern within clear spaces resembling lymphatic vessels
(Figure 1). The most common histology associated with IMPC
in mixed cases is invasive ductal carcinoma. Rarely, IMPC can
occur in a pure form or can be associated with other types of
breast cancer. IMPC has been reported to account for 3–6% of
all breast cancers [4], and these tumors have been associated
with a strong tendency to invade lymphatics with early
spread to regional lymph nodes (Figure 2).
IMPC in males is very rare, and to date there have been
nine case reports of this tumor phenotype in male patients.
Three of these reports are available in the English literature
[5–7]. The IMPC case series currently available have
included a total of 15 male patients [8–13] accounting for
only 0.005% of invasive breast cancer cases. We present a
case of this rare type of breast cancer diagnosed in a male
patient and review the current literature to date.2. Case report
The patient is a 67-year-old Caucasian man who noted a
mass in his left breast. He had a history of 0.4 mm
melanoma of the left neck treated with a wide and deep
excision several years prior to presentation. There was no
history of familial breast cancer or other types of malig-
nancies, and he denied use of hormonal medications. He
consumed alcohol in moderation and did not smoke. On
physical exam, bilateral gynecomastia was present and
more pronounced on the left side. Palpation of the left
breast revealed an approximately 2 cm ﬁrm subareolar mass
with indistinct borders. Subtle retraction of the left nipple
was noted without spontaneous or expressible discharge. No
signiﬁcant lymphadenopathy was present in the cervical,
supraclavicular, and axillary regions bilaterally. Ultrasound
and mammography of the left breast were performed which
demonstrated a 1.7 cm density. An ultrasound guided core
biopsy of the area revealed a moderately differentiated
invasive ductal carcinoma with micropapillary features. The
patient underwent a left total mastectomy with sentinel
node biopsy. Two of two sentinel nodes were positive for
carcinoma and a left axillary level I and II lymph node
dissection was subsequently performed.
Histopathological examination revealed a multifocal inva-
sive ductal carcinoma (2.1 cm, 0.5 cm, 0.3 cm) with areolar
involvement and negative surgical margins. The tumor was
moderately differentiated (histologic grade 2, nuclear grade
2, mitotic score 2), with 30% of the tumor demonstrating
micropapillary features and extensive lymphovascular inva-
sion associated with microcalciﬁcations. Nineteen out of 25
lymph nodes were positive for carcinoma, with the largest
deposit measuring 1.2 cm and demonstrated signiﬁcant
extracapsular invasion. TNM stage was pT2N3a. Immunohis-
tochemical staining was estrogen receptor (ER) positive
(100%), progesterone receptor (PR) positive (80%), HER2/
Neu negative (0%), and the proliferation index (Ki-67) was
10%. Post-operatively, the patient had a positron emission
tomography/computed tomography (PET/CT) which did not
reveal further disease spread (M0).
The patient started adjuvant chemotherapy with pacli-
taxel followed by doxorubicin plus cyclophosphamide. After-
ward, he received hormonal therapy with tamoxifen. He will
also receive axillary radiation given the extensive axillary
node metastases and evidence suggesting that invasive
micropapillary carcinoma is associated with an increased risk
of locoregional recurrence. The patient declined genetic
testing to determine if he has a BRCA mutation.3. Discussion
Review of the literature on invasive micropapillary breast
carcinoma revealed 27 retrospective cohort studies and
case series [2,8–32]. These studies were not amenable to
meta-analysis due to signiﬁcant heterogeneity among inclu-
sion criteria and data points reported. Table 1 lists the
characteristics of the studies included and Table 2 sum-
marizes the pathologic characteristics reported.
The overall incidence of invasive micropapillary carcinoma
among the retrospective cohort studies was found to be 1297
out of 331,486 cases (0.4%) of invasive breast cancer. This
Table 1 Characteristics of IMPC studies.
Study typea Total cases IMPC cases IMPC component description
Siriaunkgul and Tavassolli [2] Case series 5 5 NA
Luna-More et al. [19–21]b Case series 68 68 NA
Tressera et al. [26] Case series 15 15 NA
Middleton et al. [22] Case series 14 14 NA
Walsh and Bleiweiss [29] Case series 80 80 “Pure” (n=17), “partial” (n=63, range 5–95%)
Wei et al. [30] Case series 100 100 475% (n=42), 50–75% (n=20), 25–50% (n=15),
o25% (n=23)
Varga et al. [27] Case series 11 11 NA
Li et al. [18] Case series 40 40 “Pure” (n=9), “mixed” (n=31)
Chen et al. [14] Case series 100 100 NA
Shi et al. [25] Case series 188 188 “Pure” (n=27), “mixed” (n=161)
Kim et al. [11] Cohort 250 38 450% (n=17), o50% (n=21)
Nassar et al. [12] Cohort 1400 83 480% (n=10), “minor proportion” (n=73)
Kuroda et al. [17] Cohort 671 27 “Some”
De La Cruz et al. [15] Cohort 1056 16 “Pure” (n=10), “mixed” (n=6)
Zekioglu et al. [32] Cohort 2022 53 475% (n=47), o75% (n=6)
Pettinato et al. [13] Cohort 1635 62 50–100% (n=40), 25–50% (n=12),
o25% (n=10)
Yu et al. [31] Cohort 2753 72 470% (n=72)
Vingiani et al. [28] Cohort 13,278 49 “Pure” (n=49)
Paterakos et al. [23] Cohort 1287 21 “Pure” (n=21)
Gocke et al. [10] Cohort 2718 103 “Pure” (n=20), “mixed” (n=83)
Ren et al. [24] Cohort 5625 86 NA
Chen et al. [8,9]b Cohort 297,735 636 NA
Guo et al. [16] Cohort 1056 51 475% (n=19), 50–75% (n=12), 25–50% (n=11),
o25% (n=9)
aAll studies were retrospective.
bMultiple papers published as more cases were added to their series, numbers listed reﬂect most recent publication.
Table 2 Pathologic characteristics of IMPC tumors.
Present
(n)
Total cases
(n)
Percentage
(%)
IMPCa 1297 331,486 0.4b
LVI 638 866 73.7
LN
metastasis
1267 1780 71.2
ER (+) 1176 1603 73.4
PR (+) 945 1511 62.5
HER-2/neu
(+)
227 560 40.5
IMPC – invasive micropapillary carcinoma, LVI – lymphovas-
cular invasion, LN – lymph node, ER – estrogen receptor, PR –
progesterone receptor.
aDerived from cohort studies only, case series excluded
from calculation.
bExcluding Chen et al. [9] SEER database, the IMPC
incidence was 1.9%.
J.T. Stranix et al.46falls well below the 3–6% IMPC incidence rate reported
previously [4]. Excluding the study by Chen et al. [8,9] using
the National Cancer Institute's Surveillance, Epidemiology,
and End Results (NCI SEER) database, the reported incidencerises to 537 out of 27,876 cases (1.93%) of newly diagnosed
invasive breast cancer. This difference may reﬂect a degree
of bias related to the retrospective nature of the cohort
studies published to date on this rare tumor phenotype.
All included studies demonstrated signiﬁcant lymphotrophic
behavior of tumors with an IMPC phenotype. Lymphovascular
invasion was reported in 638 out of 866 IMPC cases (73.7%) and
positive lymph node metastases were present in 1267out of
1780 (71.2%). The hormonal status of IMPC among reported
cases was found to be ER positive in 1176 of 1603 (73.4%) and
PR positive in 945 of 1511 (62.5%) cases. Her-2/neu positivity
was present in 227 of 560 (40.5%) cases.
Follow up data was provided by eighteen of the studies
included in this review (Table 3). Variable rates of local
recurrence and distant metastasis were reported ranging
from 6 to 80% and 1 to 49% respectively. Mean time to local
recurrence ranged from 14 to 32 months and three studies
reported mean time to distant metastasis between 36 and 56
months after diagnosis. The reported incidence of patients
dying from their IMPC disease ranged from 5 to 80%.
Several studies compared their cohort of IMPC patients to
invasive ductal carcinoma (IDC) controls matched by disease
stage and revealed a signiﬁcantly higher incidence of lymph
node metastasis in IMPC patients, particularly for early
stage breast cancer [9–12,14,23–25,28,31,32]. Yu et al.
[31] demonstrated a signiﬁcantly worse local recurrence
free survival for IMPC compared with matched IDC controls,
Table 3 Summary of available data on IMPC patient survival.
Patients
(n)
Local
recurrence
Distant
metastasis
Died of
disease
Control Survival effect
De La Cruz et al. [15] 16 – 3 (19%) 4 (25%) – –
Zekioglu et al. [32] 36 8 (22%) 9 (25%) 10 (28%) IDC-NOS NS
Pettinato et al. [13] 41 29 (71%) 20 (49%) 20 (49%) – –
Vingiani et al. [28] 49 3 (6%) 4 (8%) 5 (10%) IDC-NOS NS
Paterakos et al. [23] 21 – – – IDC-NOS NS
Tressera et al. [26] 15 4 (27%) – 4 (27%) – –
Middleton et al. [22] 11 9 (82%) – 5 (45%) – –
Gocke et al. [10] 87 6 (7%) 20 (23%) 21 (24%) IDC NS
Li et al. [18] 40 9 (23%) – 2 (5%) – –
Chen et al. [14] 98 11 (11%) 38 (39%) 36 (37%) IDC-NOS Lower overall survival
Luna-More et al. [19] 54 – 4 (7%) 20 (37%) – –
Yu et al. [31] 72 11 (15%) 4 (6%) 9 (13%) IDC Higher local
recurrence rate
Siriaunkgul et al. [2] 5 1 (20%) – 4 (80%) – –
Shi et al. [25] 115 – – – IDC Stage III IMPC poorer
RFS
and BCSS vs. Stage III
IDC
Kim et al. [11] 38 4 (10.5%) 13 (34.2%) – IDC NS
Ren et al. [24] 86 14 (16.3%) 21 (24.4%) 8 (9.3%) IDC-NOS NS
Chen et al. [8,9] 627 – – – IDC NS
Nassar et al. [12] 83 4 (5%) 1 (1%) 38 (46%) IDC NS
IDC – invasive ductal carcinoma, IDC-NOS – invasive ductal carcinoma not otherwise speciﬁed, NS – No signiﬁcant difference, BCSS –
Breast Cancer Speciﬁc Survival, and RFS – Recurrence Free Survival.
47Invasive micropapillary carcinomahowever no difference was seen on overall survival analysis.
This may be associated with loss of caveolin-1 expression by
IMPC stromal ﬁbroblasts [24].
Chen et al. [14] reported IMPC to be signiﬁcantly
associated with lower overall survival on univariate analysis,
however, their control IDC group was not matched for tumor
stage. Their IMPC cohort had a mean tumor size of 3.38 cm
and 84.8% of these patients had positive lymph node
metastasis at time of diagnosis compared to an average
IDC tumor size of 2.39 cm and only 50% of IDC patients had
positive lymph nodes. Their results are most likely due to
the more advanced stage of disease in their IMPC cohort,
rather than a product of the IMPC phenotype itself.
Shi et al. [25] compared 188 IMPC patients to 1289
unmatched controls with IDC. They demonstrated worse
recurrence free survival (p=0.034) and breast cancer-
speciﬁc survival (p=0.004) for stage III IMPC patients
compared with stage III IDC. No difference was seen
between groups with stage I and II disease. There were
clinically signiﬁcant baseline differences between the IMPC
and IDC groups in this study, however, with IMPC demon-
strating far more advanced disease at time of diagnosis.
Following the trajectory of more advanced disease in the
IMPC cohort, the observed difference between stage III
patients could be related to a higher number of stage IIIB
or C patients in the IMPC group compared to the IDC group,
but this distinction is not evaluated.
The largest IMPC study to date was performed by Chen
et al. [8,9] utilizing the NCI SEER database. Although their
results conﬁrmed the increased propensity of IMPC to demon-
strate lymph node involvement compared to IDC (52.0% vs.34.6%), they found 5-year disease-speciﬁc (DSS) and overall
survival (OS) rates that compared favorably to that of IDC
(91.8% and 82.9% vs. 88.6% and 80.5% respectively). On
multivariate analysis, larger tumor size, four or more positive
lymph nodes, and radiation treatment were independent
predictors of DSS or OS for IMPC patients. They conclude that
despite its aggressive initial presentation with a higher clinical
stage at diagnosis, the rate of distant metastases appears
similar to that of IDC. Compared to the average number of
estrogen receptor positive (ER+) IMPC tumors in other studies,
however, their cohort of IMPC patients demonstrated a much
higher incidence of ER+tumors (84.1% vs. 68.8%) and may
have positively inﬂuenced their survival results.
Breast cancer mortality has been associated with lympho-
vascular invasion and regional lymph node metastasis, but no
study to date has been able to demonstrate that IMPC is
associated with a decreased overall survival compared to IDC.
This may be due to small cohort size, limited follow-up, and
the uniformly retrospective nature. In addition, many of the
studies vary in their deﬁnition of IMPC tumors based on
percentage of the neoplasm demonstrating micropapillary
histology. These ranged from any IMPC histology present to
completely pure IMPC tumors and the lack of deﬁned
pathologic criteria for diagnosing IMPC is illustrated by the
signiﬁcant variation among reported IMPC incidences.
Despite the heterogeneity of inclusion criteria for per-
centage of the IMPC component of invasive breast tumors
included in studies published to date, it is apparent that the
presence of IMPC histology indicates a tumor of an aggres-
sive nature that is likely to metastasize to regional lymph
nodes. This suggests a role for sentinel lymph node biopsy in
J.T. Stranix et al.48these patients when diagnosed on core needle biopsy and
may indicate patients who would beneﬁt from axillary
radiation postoperatively. The IMPC data currently available
indicates a strong trend towards a higher initial stage at
diagnosis and possibly an increased risk of loco-regional
recurrence, but remains underpowered to elucidate the
prognostic effect of IMPC phenotype on survival.
4. Conclusions
We present a rare case of stage IIIC IMPC in a male patient who
is status post unilateral mastectomy with axillary lymph node
dissection and is currently undergoing adjuvant treatment with
chemotherapy followed by hormonal therapy and radiation.
From a review of the literature, there appears to be a marked
propensity for tumors with an IMPC component to demonstrate
an early and high rate of lymphatic metastasis. This is a known
risk factor for increased regional recurrence, distant metas-
tases, and decreased disease free and overall survival. Further
studies are warranted to establish the potential of this unique
histologic phenotype to serve as a prognostic indicator and
guide tumor-speciﬁc oncologic therapy.
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Clinical practice points:- IMPC of the breast is a rare histologic variant of invasive
ductal carcinoma.- Tumors with an IMPC component demonstrate a propen-
sity for lymphatic invasion with early spread to regional
lymph nodes.- Data currently available indicates a strong trend towards
a higher initial stage at diagnosis and possibly an
increased risk of loco-regional recurrence.- Sentinel lymph node biopsy should be considered in these
patients when diagnosed with an IMPC component on
core needle biopsy and may indicate patients who would
beneﬁt from axillary radiation postoperatively.- The prognostic impact of the IMPC phenotype on both
disease-free and overall survival, however, remains to be
determined.
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